Clinical Trials
11 trialsNCT05534620 2026-05-20
Effect of Moderate Renal Impairment and Race/Ethnicity on Treosulfan Pharmacokinetics
medac GmbH
Phase 1 Completed
NCT03961919 2023-11-18
FLAT-Auto
IRCCS San Raffaele
Phase 2 Completed
NCT01063647 2023-11-03
Dose-range Finding Treosulfan-based Conditioning
medac GmbH
Phase 1/2 Completed
NCT00796068 2023-02-17
Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation in Treating Patients With Hematological Cancer Who Are Undergoing Umbilical Cord Blood Transplant
Fred Hutchinson Cancer Center
Phase 2 Completed
NCT00860574 2021-06-22
Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia
Fred Hutchinson Cancer Center
Phase 2 Completed
NCT00822393 2020-07-30
Clinical Phase III Trial Treosulfan-based Conditioning Versus Reduced-intensity Conditioning (RIC)
medac GmbH
Phase 3 Completed
NCT01772953 2016-10-12
Treosulfan/Fludarabine/Low Dose TBI as a Preparative Regimen for Children With AML/MDS Undergoing Allo HCT
Center for International Blood and Marrow Transplant Research
Phase 2 Completed
NCT00491634 2015-12-02
Treosulfan-based Conditioning for Transplantation in AML/MDS
Sheba Medical Center
Phase 2 Completed
NCT00253513 2012-06-01
Treosulfan and Fludarabine in Treating Younger Patients Who Are Undergoing a Donor Stem Cell Transplant for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome
OHSU Knight Cancer Institute
Phase 1/2 Completed
NCT01063660 2010-02-05
Treosulfan Based Conditioning Acute Myeloid Leukaemia (AML)
medac GmbH
Phase 2 Completed
NCT01062490 2010-02-04
Treosulfan Based Conditioning Myelodysplastic Syndrome (MDS)
medac GmbH
Phase 2 Completed